| HOME >> BIOLOGY >> TECHNOLOGY |
About ARIUS
ARIUS is a biotechnology company discovering and developing the next
wave of antibody therapeutics. Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
and selects antibodies based on their functional ability to affect disease.
This antibody generation engine has enabled ARIUS to assemble a portfolio
of more than 500 antibody candidates. In addition to the antibodies it is
developing in-house, ARIUS has ongoing partnerships with key biotechnology
and drug development companies. ARIUS is listed on the TSX under the symbol
"ARI". For further information, visit http://www.ariusmabs.com
Financial Information to Follow:
ARIUS RESEARCH INC.
(A DEVELOPMENT STAGE COMPANY)
INTERIM BALANCE SHEETS
(Unaudited)
-------------------------------------------------------------------------
May 31, November 30,
2008 2007
$ $
-------------------------------------------------------------------------
Assets
Current assets:
Cash and cash equivalents 8,543,124 5,635,365
Short-term investments - 6,825,190
Receivables 185,672 230,126
Refundable tax credits 600,000 400,000
Prepaid expenses
'/>"/>
| SOURCE ARIUS Research Inc. Copyright©2008 PR Newswire. All rights reserved |